These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 36781852)

  • 1. Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment.
    Werba G; Weissinger D; Kawaler EA; Zhao E; Kalfakakou D; Dhara S; Wang L; Lim HB; Oh G; Jing X; Beri N; Khanna L; Gonda T; Oberstein P; Hajdu C; Loomis C; Heguy A; Sherman MH; Lund AW; Welling TH; Dolgalev I; Tsirigos A; Simeone DM
    Nat Commun; 2023 Feb; 14(1):797. PubMed ID: 36781852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications.
    Park JK; Jeong HO; Kim H; Choi JH; Lee EM; Kim S; Jang J; Choi DW; Lee SH; Kim KM; Jang KT; Lee KH; Lee KT; Lee MW; Lee JK; Lee S
    Mol Cancer; 2024 May; 23(1):87. PubMed ID: 38702773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the dynamic transcriptional landscape of Treg subpopulations in pancreatic ductal adenocarcinoma: Insights from single-cell RNA sequencing analysis with a focus on CTLA4 and TIGIT.
    Miraki Feriz A; Khosrojerdi A; Erfanian N; Azarkar S; Sajjadi SM; Shojaei MJ; Vaferi MJ; Safarpour H; Racanelli V
    Immunobiology; 2024 Jul; 229(4):152822. PubMed ID: 38852289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 5. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cell mapping reveals several immune subsets associated with liver metastasis of pancreatic ductal adenocarcinoma.
    Zhang Z; Zhu XQ; Yang F; Lai NN; Zhu L; Cole K; Hu BY; Li TE; Zhu Y; Zhang LM; Wang S; Zheng Y; Mao H; Zhao Y; Bruns C; Vago R; Tu B; Wong JWH; Fu DL; Qin LX; Dong QZ
    Med; 2023 Oct; 4(10):728-743.e7. PubMed ID: 37633269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-cell RNA-seq reveals characteristics in tumor microenvironment of PDAC with MSI-H following neoadjuvant chemotherapy with anti-PD-1 therapy.
    Chen K; Ma Y; Liu X; Zhong X; Long D; Tian X; Zheng L; Yang Y
    Cancer Lett; 2023 Nov; 576():216421. PubMed ID: 37778681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of PDAC subtype heterogeneity and therapy response.
    Espinet E; Klein L; Puré E; Singh SK
    Trends Cancer; 2022 Dec; 8(12):1060-1071. PubMed ID: 36117109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.
    George B; Kudryashova O; Kravets A; Thalji S; Malarkannan S; Kurzrock R; Chernyavskaya E; Gusakova M; Kravchenko D; Tychinin D; Savin E; Alekseeva L; Butusova A; Bagaev A; Shin N; Brown JH; Sethi I; Wang D; Taylor B; McFall T; Kamgar M; Hall WA; Erickson B; Christians KK; Evans DB; Tsai S
    Gastroenterology; 2024 May; 166(5):859-871.e3. PubMed ID: 38280684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions.
    Lin W; Noel P; Borazanci EH; Lee J; Amini A; Han IW; Heo JS; Jameson GS; Fraser C; Steinbach M; Woo Y; Fong Y; Cridebring D; Von Hoff DD; Park JO; Han H
    Genome Med; 2020 Sep; 12(1):80. PubMed ID: 32988401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma.
    Li X; Hou W; Xiao C; Yang H; Zhao C; Cao D
    Cell Oncol (Dordr); 2024 Oct; 47(5):1561-1578. PubMed ID: 39008192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
    Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
    Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes.
    Eyres M; Lanfredini S; Xu H; Burns A; Blake A; Willenbrock F; Goldin R; Hughes D; Hughes S; Thapa A; Vavoulis D; Hubert A; D'Costa Z; Sabbagh A; Abraham AG; Blancher C; Jones S; Verrill C; Silva M; Soonawalla Z; Maughan T; Schuh A; Mukherjee S; O'Neill E
    Gastroenterology; 2021 Aug; 161(2):653-668.e16. PubMed ID: 33915173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
    Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
    Front Immunol; 2018; 9():1878. PubMed ID: 30158932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.
    O'Kane GM; Grünwald BT; Jang GH; Masoomian M; Picardo S; Grant RC; Denroche RE; Zhang A; Wang Y; Lam B; Krzyzanowski PM; Lungu IM; Bartlett JMS; Peralta M; Vyas F; Khokha R; Biagi J; Chadwick D; Ramotar S; Hutchinson S; Dodd A; Wilson JM; Notta F; Zogopoulos G; Gallinger S; Knox JJ; Fischer SE
    Clin Cancer Res; 2020 Sep; 26(18):4901-4910. PubMed ID: 32156747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer.
    Kumar S; Singh SK; Srivastava P; Suresh S; Rana B; Rana A
    Adv Cancer Res; 2023; 159():113-143. PubMed ID: 37268394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-associated neutrophils upregulate Nectin2 expression, creating the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma.
    Luo H; Ikenaga N; Nakata K; Higashijima N; Zhong P; Kubo A; Wu C; Tsutsumi C; Shimada Y; Hayashi M; Oyama K; Date S; Abe T; Ideno N; Iwamoto C; Shindo K; Ohuchida K; Oda Y; Nakamura M
    J Exp Clin Cancer Res; 2024 Sep; 43(1):258. PubMed ID: 39261943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
    Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-cell RNA sequencing highlights epithelial and microenvironmental heterogeneity in malignant progression of pancreatic ductal adenocarcinoma.
    Li J; Wei T; Ma K; Zhang J; Lu J; Zhao J; Huang J; Zeng T; Xie Y; Liang Y; Li X; Zhang Q; Liang T
    Cancer Lett; 2024 Mar; 584():216607. PubMed ID: 38246225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.